What is Lipfendra?
Lipfendra (enlicitide) is the first oral PCSK9 inhibitor: a once-daily pill, made by Merck, that lowers LDL cholesterol (LDL-C) by about 56 to 59%. The FDA approved it in July 2026 for adults with high cholesterol, including heterozygous familial hypercholesterolemia.
Every other option in the class needs an injection: evolocumab (Repatha), alirocumab (Praluent), inclisiran (Leqvio) and lerodalcibep (Lerochol). For the bigger picture, see PCSK9 inhibitors explained.
How well does Lipfendra lower LDL?
About as well as the injectable PCSK9 inhibitors. Compared with placebo at 24 weeks, Lipfendra lowered LDL by 56% in the CORALreef Lipids trial and by 59% in CORALreef HeFH, in people with familial hypercholesterolemia (prescribing information).
Source
Navar AM, Mikhailova E, Catapano AL, et al. “A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.” New England Journal of Medicine (2026).
View paperIn CORALreef Lipids, which enrolled 2,909 people, Lipfendra also lowered ApoB by about 53% and Lp(a) by about 28% compared with placebo, and 70% of people on it reached an LDL-C under 70 mg/dL along with at least a 50% drop (ACC). The Lp(a) drop is in line with what the injectable PCSK9 inhibitors do.
Key Takeaway
Lipfendra lowers LDL about as much as the injectable PCSK9 inhibitors. It is more convenient: a pill you take at home, with no injection device to learn.
How do you take Lipfendra?
Take one 20 mg tablet each morning on an empty stomach with water, black coffee, or plain tea, then wait at least 30 minutes before eating or drinking anything else. Swallow it whole, without splitting, crushing, or chewing it.
Timing matters because very little of the drug is absorbed even under ideal conditions. In studies, taking it 30 minutes after a meal cut the amount reaching the bloodstream by about half (prescribing information). Some osteoporosis pills follow a similar rule.
What are the side effects?
Side effects in the trials were generally similar to placebo. In CORALreef Lipids, 64% of people on Lipfendra and 62% on placebo reported any adverse event, and 3% vs 4% stopped because of one.
In people with familial hypercholesterolemia, diarrhea (7% vs 2%) and dizziness (9% vs 4%) were more common than with placebo, per the prescribing information.
How much does Lipfendra cost?
Merck set Lipfendra's list price at $10.50 a day, about $315 for a 30-day supply (Chicago Sun-Times), lower than the list price of Repatha. Few people pay list price, since your cost depends on your insurance's step-therapy requirements and formulary tier, or, if you pay cash, on the pharmacy's price.
Who might benefit most from Lipfendra?
Lipfendra suits people who need a PCSK9 inhibitor but would rather not inject. Discuss it with your clinician if you:
- Need a PCSK9 inhibitor but would prefer to avoid self-injections
- Have needle aversion that has kept you from starting an injectable option you otherwise qualify for
- Have elevated Lp(a) in addition to elevated LDL or ApoB
- Have statin intolerance and are looking for a non-statin oral option with a strong LDL-lowering effect
It fits less well if a fixed morning routine with a 30-minute wait before breakfast would be tough to keep.
What we don't know yet
We don't yet know whether Lipfendra reduces heart attacks and strokes. Its approval was based on LDL lowering, and its cardiovascular outcomes trial, CORALreef Outcomes, is still running (ClinicalTrials.gov NCT06008756).
New cholesterol drugs normally go through this stage. Lowering LDL through LDL receptors has meant fewer cardiovascular events in the outcomes trials of statins and of the antibody PCSK9 inhibitors, Repatha and Praluent.
If you read that Lipfendra has already been proven to prevent heart attacks, that claim runs ahead of the evidence. The LDL reduction is substantial, and the long-term outcomes trial is still running.
How do you get Lipfendra?
Through insurance with prior authorization, or by paying cash. Like other PCSK9 inhibitors, Lipfendra faces step therapy in many plans, which often means a documented trial of a statin and sometimes ezetimibe first.
People who would rather skip the prior-authorization wait can pay cash.
Summary
Lipfendra helps people who need a PCSK9 inhibitor but have avoided one because of the needle. If an injectable regimen already works for you, you can stay on it, and Lipfendra still lacks the outcomes evidence that Repatha and Praluent have. For the right patient, it removes the biggest practical barrier to starting treatment.
At Preval Health, licensed clinicians in our partner network can prescribe Lipfendra through direct cash access, with no prior authorization wait. We tell you plainly when the evidence is still developing.